SGLT2 Inhibitors in Cardiovascular Diseases

Tong Liu, MD, PhD, FESC, FHRS, ISNE-F, Youth Committee member of ISE, is a Professor of Cardiology at Tianjin Medical University and Deputy Director of the Tianjin Institute of Cardiology. With over 200 publications, he specializes in cardiac remodeling, arrhythmic disorders, and cardiovascular aging, and is on the Stanford Top 2% Scientists list. Dr. Liu leads research on biomarkers of cardiovascular aging and developing novel cardiac age models. He serves on the editorial boards of leading journals such as Pacing and Clinical Electrophysiology and BMC Cardiovascular Disorders and is Editor-in-Chief of Current Cardiology Reviews. His work focuses on molecular biology, clinical research, and the potential role of SGLT-2 inhibitors in cardiovascular disease. Dr. Liu has also authored and edited nine books, including AI Augmented ECG Technology from Springer. His extensive research and leadership make him a prominent figure in cardiovascular aging and translational cardiology.

• Section I. Introduction and Overview1. Overview of SGLT2 Inhibitors and Cardiovascular Disease2. The Development of SGLT2 Inhibitors and Their Expanding Role in Cardiovascular DiseaseSection II. Mechanisms of SGLT2 Inhibition in Cardiovascular Disease3. Molecular Mechanisms of SGLT2 Inhibition in Cardiovascular Systems4. SGLT2 Inhibition and Cardiovascular Pathophysiology5. Impact of SGLT2 Inhibition on Cardiovascular RemodelingSection III. Clinical Evidence and Applications6. Cardiovascular Benefits of SGLT2 Inhibitors in Type 2 Diabetes7. SGLT2 Inhibitors in Heart Failure8. SGLT2 Inhibitors in Lipid Metabolism Disease. Focus on Atherosclerotic Cardiovascular9. SGLT2 Inhibitors in Arrhythmias. Special Focus on Atrial Fibrillation and Syncope10. SGLT2 Inhibitors vs. DPP4 Inhibitors in Cardiovascular Disease11. SGLT2 Inhibitors in Cardiorenal and Metabolic ProtectionSection IV. Efficacy and Safety of SGLT2 in Cardiovascular Diseases12. Common Adverse Effects and Long-Term Safety13. Efficacy and Safety in Special PopulationsSection V. Future Directions and Unanswered Questions14. Future Perspectives on SGLT2 Inhibitors in Cardiovascular Disease15. Unanswered Questions and Ongoing Clinical Trials